ArticleAnnals of hematology2024

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

Jean-Jacques Kiladjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.